Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Anjie Biomedical Technology
Main focus: Next generation CAR-T cells
Company stage: Clinical
Diseases: Solid tumours
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Guanzhou, China
Anjie Biomedical Technology develops next generation CAR-T cells for solid tumour treatment. The company uses CRISPR to knock out PD-1 from its CAR-T cell products, in order to optimise efficacy and safety.